NCT03430258 is a NA clinical trial of high-flow nasal cannula in Blunt Thoracic Injury, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT03430258?

NCT03430258 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT03430258?

Interventions in NCT03430258: high-flow nasal cannula, Conventional oxygen therapy.

What condition does NCT03430258 study?

NCT03430258 studies Blunt Thoracic Injury, Lung Ultrasound Score.

Is NCT03430258 still recruiting?

NCT03430258 is currently status unknown. Last updated 12 February 2018.

Last reviewed 2018-02-12 · How we verify

NCT03430258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-flow Nasal Cannula Oxygen Therapy With the Chest Trauma Patients

Status unknown NA Last updated 12 February 2018

What this trial tests

NA trial testing high-flow nasal cannula in Blunt Thoracic Injury in 90 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
30 March 2019

30 March 2019

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 March 2018
Primary completion	30 March 2019
Estimated completion	30 March 2019

Drugs / interventions tested

high-flow nasal cannula
Conventional oxygen therapy

Conditions studied

Blunt Thoracic Injury — all drugs for Blunt Thoracic Injury →
Lung Ultrasound Score — all drugs for Lung Ultrasound Score →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Blunt Thoracic Injury or Lung Ultrasound Score. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective randomized controlled study was conducted in the emergency intensive care units (EICU) of the second affiliated hospital Zhejiang university school of medicine, a large tertiary university hospital in HangZhou, China.The aim of this randomized study was to compare the effectiveness of high-flow nasal cannula with conventional oxygen therapy in ICU patients with blunt thoracic injury.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

High-flow nasal cannulae for respiratory support in adult intensive care patients.
Corley A, Rickard CM, Aitken LM, Johnston A, et al · · 2017 · cited 44× · PMID 28555461 · DOI 10.1002/14651858.cd010172.pub2
High-flow nasal cannulae for respiratory support in adult intensive care patients.
Lewis SR, Baker PE, Parker R, Smith AF. · · 2021 · cited 43× · PMID 33661521 · DOI 10.1002/14651858.cd010172.pub3

Verify or expand the search:

Other trials of high-flow nasal cannula

Trials testing the same drug.

NCT06425406 — Application of HFNC for the Prevention of Hypoxemia During Perioperative Anesthetic-induced Intubation in Children: A Ra · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03430258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 12 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing